和黄医药与君实生物(01877.HK)在中国启动肿瘤联合疗法二期临床试验
和黄医药公布,旗下产品「索凡替尼」与君实生物(01877.HK)的PD-1单克隆抗体「拓益」,联合於中国启动治疗晚期实体瘤患者的II期临床试验。
该公司指,是次临床试验是双方全球合作的一部分,旨在测试两项产品的联合疗法同时针对肿瘤微环境中多种细胞类型和信号通路的协同抗肿瘤作用。
「索凡替尼」为一款口服抗血管生成免疫逃逸激(酉每)抑制剂,作为非胰腺神经内分泌瘤的新药上市申请已於去年底获中国国家药监局药品审评中心纳入优先审评,并被美国食品药品监督管理局授予孤儿药资格,用於治疗胰腺神经内分泌瘤。而「拓益」已於2018年获国家药监局批准上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.